TDC
KNSA icon

Thompson Davis & Co’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Thompson Davis & Co’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-200
Closed -$3K – 756
2018
Q2 		$3K Buy
+200
New +$3.62K 0.01% 581

Other funds holding KNSA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thompson Davis & Co's KNSA Position: Q3 2018 in Review

Thompson Davis & Co sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2018, closing a stake of 200 shares — an estimated $3K sold.

Thompson Davis & Co first reported a position in KNSA in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 55 funds tracked by Wall St. Rank hold KNSA as of Q3 2018.

  • Thompson Davis & Co reported no remaining Kiniksa Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 200 Kiniksa Pharmaceuticals shares in Q3 2018, an estimated $3K.
  • Thompson Davis & Co first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Thompson Davis & Co's Kiniksa Pharmaceuticals position peaked at $3K in Q2 2018.
  • 55 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.